A robust R&D project portfolio optimization model for pharmaceutical contract research organizations

被引:40
作者
Hassanzadeh, Farhad [1 ]
Modarres, Mohammad [2 ]
Nemati, Hamid R. [1 ]
Amoako-Gyampah, Kwasi [1 ]
机构
[1] Univ N Carolina, Bryan Sch Business & Econ, Dept Informat Syst & Supply Chain Management, Greensboro, NC 27412 USA
[2] Sharif Univ Technol, Dept Ind Engn, Tehran 113659363, Iran
关键词
Pharmaceutical contract research; organization (CRO); Research and Development (R&D); Project selection and scheduling; Uncertainty; Robust optimization; REAL OPTIONS; SELECTION; RISKS; DETERMINANTS; INFORMATION; ALLOCATION; INNOVATION;
D O I
10.1016/j.ijpe.2014.07.001
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
Pharmaceutical drug Research and Development (R&D) outsourcing to contract research organizations (CROs) has experienced a significant growth in recent decades and the trend is expected to continue. A key question for CROs and firms in similar environments is which projects should be included in the firm's portfolio of projects. As a distinctive contribution to the literature this paper develops and evaluates a business support tool to help a CRO decide on clinical R&D project opportunities and revise its portfolio of R&D projects given the existing constraints, and financial and resource capabilities. A new mathematical programming model in the form of a capital budgeting problem is developed to help revising and rescheduling of the project portfolio. The uncertainty of pharmaceutical R&D cost estimates in drug development stages is captured to mimic a more realistic representation of pharmaceutical R&D projects, and a robust optimization approach is used to tackle the uncertain formulation. An illustrative example is presented to demonstrate the proposed approach. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:18 / 27
页数:10
相关论文
共 63 条
[1]   Outsourcing: Where's the value? [J].
Alexander, M ;
Young, D .
LONG RANGE PLANNING, 1996, 29 (05) :728-730
[2]   Industry-sponsored clinical research - A broken system [J].
Angell, Marcia .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (09) :1069-1071
[3]   Accelerating drug discovery: creating the right environment [J].
Arlington, S .
DRUG DISCOVERY TODAY, 1997, 2 (12) :547-553
[4]   Robust optimization for resource-constrained project scheduling with uncertain activity durations [J].
Artigues, Christian ;
Leus, Roel ;
Nobibon, Fabrice Talla .
FLEXIBLE SERVICES AND MANUFACTURING JOURNAL, 2013, 25 (1-2) :175-205
[5]  
Association of Clinical Research Organizations, 2013, CRO MARK REP
[6]  
Bauer H.H., 2000, INT BUS REV, V9, P703, DOI [10.1016/s0969-5931(00)00028-7, DOI 10.1016/S0969-5931(00)00028-7, 10.1016/S0969-5931(00)00028-7]
[7]   Robust optimization - methodology and applications [J].
Ben-Tal, A ;
Nemirovski, A .
MATHEMATICAL PROGRAMMING, 2002, 92 (03) :453-480
[8]  
Benli ÖS, 2002, INT J IND ENG-THEORY, V9, P301
[9]   The price of robustness [J].
Bertsimas, D ;
Sim, M .
OPERATIONS RESEARCH, 2004, 52 (01) :35-53
[10]   Robust discrete optimization and network flows [J].
Bertsimas, D ;
Sim, M .
MATHEMATICAL PROGRAMMING, 2003, 98 (1-3) :49-71